Telix Pharmaceuticals acquires next-gen therapeutic assets and research facility from ImaginAb

From GlobeNewswire: 2025-01-12 17:04:58

Telix Pharmaceuticals Limited has entered into an asset purchase agreement with ImaginAb, Inc. to acquire a pipeline of next-generation therapeutic candidates and a protein engineering research facility. The transaction includes early-stage drug candidates against DLL31 and integrin αvβ62 targets. Telix will pay up to $185 million based on key development and commercial milestones. The acquisition will enhance Telix’s research capabilities and allow exploration of new disease areas with radiotherapeutic technology. ImaginAb will focus on developing its lead imaging candidate, CD8 ImmunoPET, after the transaction with Telix closes. Telix is listed on the ASX and Nasdaq.



Read more at GlobeNewswire: Telix to Acquire Next-Generation Therapeutic Assets and